{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:05Z","timestamp":1789749485334,"version":"4.0.1"},"reference-count":72,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background: Pyoderma gangrenosum (PG) is a rare inflammatory cutaneous disorder that frequently occurs in association with systemic diseases such as inflammatory bowel disease (IBD). This case report describes a 23-year-old female with Crohn\u2019s disease (CD) who developed PG and was successfully treated with adalimumab. The objective of this study is to present the clinical course, treatment approach, and outcomes while reviewing the existing literature on the efficacy of adalimumab in PG management. Methods: A case report is presented, detailing clinical presentation, diagnostic evaluation, and treatment strategy. Additionally, a systematic review was conducted using PubMed to assess studies on adalimumab in PG, focusing on treatment response, remission rates, and adverse effects. Results: The patient presented with ulcerative lesions on her lower extremities and sacroiliitis. After corticosteroid therapy, adalimumab was initiated, leading to significant ulcer healing, reduced back pain, and CD remission. The systematic review identified seven studies on adalimumab in PG. Findings suggest that adalimumab is effective in steroid-refractory cases, with remission achieved in a significant proportion of patients. The most common adverse effects were infections, but overall, adalimumab showed a favorable safety profile. Conclusions: This case highlights the importance of early diagnosis and multidisciplinary management of PG in CD patients. Adalimumab appears to be a promising therapeutic option, particularly for steroid-resistant PG, though further research is needed to establish standardized treatment protocols.<\/jats:p>","DOI":"10.3390\/clinpract15030057","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T10:51:57Z","timestamp":1741690317000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pyoderma Gangrenosum in a Patient with Crohn\u2019s Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature"],"prefix":"10.3390","volume":"15","author":[{"given":"Fotios S.","family":"Fousekis","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mpakogiannis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4130-3306","authenticated-orcid":false,"given":"Emmanouil","family":"Karampinis","sequence":"additional","affiliation":[{"name":"Second Dermatology Department, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"},{"name":"Department of Dermatology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, 41110 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna Nefeli","family":"Mastorogianni","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios K.","family":"Christodoulou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Papoutsaki","sequence":"additional","affiliation":[{"name":"1st Departament of Dermatology-Venereology, Faculty of Medicine, National and Kapodistrian University of Athens, \u201cA. Sygros\u201d Hospital for Skin and Venereal Diseases, 16121 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Zampeli","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Alexandra General Hospital, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos H.","family":"Katsanos","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma Gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/11595240-000000000-00000","article-title":"Etiology and Management of Pyoderma Gangrenosum","volume":"13","author":"Ahronowitz","year":"2012","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, Mortality, and Disease Associations of Pyoderma Gangrenosum in the United Kingdom: A Retrospective Cohort Study","volume":"132","author":"Langan","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma Gangrenosum: Clinicopathologic Correlation and Proposed Diagnostic Criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/09546630410031909","article-title":"Review of 26 Cases of Classical Pyoderma Gangrenosum: Clinical and Therapeutic Features","volume":"15","author":"Vidal","year":"2004","journal-title":"J. Dermatol. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma Gangrenosum: A Retrospective Review of Patient Characteristics, Comorbidities and Therapy in 103 Patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.cpm.2021.06.002","article-title":"Pyoderma Gangrenosum","volume":"38","author":"Barbe","year":"2021","journal-title":"Clin. Podiatr. Med. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_9","first-page":"e4213","article-title":"Pyoderma Gangrenosum in the Absence of Any Underlying Predisposing Condition: A Diagnostic Dilemma","volume":"11","author":"Jain","year":"2019","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/iwj.13466","article-title":"The Great Imitator with No Diagnostic Test: Pyoderma Gangrenosum","volume":"17","year":"2020","journal-title":"Int. Wound J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.3748\/wjg.14.5471","article-title":"De Atypical Presentation of Pioderma Gangrenosum Complicating Ulcerative Colitis: Rapid Disappearance with Methylprednisolone","volume":"14","author":"Aseni","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2230.1984.tb00822.x","article-title":"Histiocytosis X in an Adult Mimicking Pyoderma Gangrenosum*","volume":"9","author":"Norris","year":"1984","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005792-200001000-00004","article-title":"Pyoderma Gangrenosum A Comparison of Typical and Atypical Forms with an Emphasis on Time to Remission. Case Review of 86 Patients from 2 Institutions","volume":"79","author":"Bennett","year":"2000","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaad.2017.11.063","article-title":"Neutrophilic Dermatoses","volume":"79","author":"Ashchyan","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa013383","article-title":"Skin Ulcers Misdiagnosed as Pyoderma Gangrenosum","volume":"347","author":"Weenig","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma Gangrenosum: Treatment Options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jid.2020.04.019","article-title":"Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum","volume":"141","author":"Haag","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e11933","DOI":"10.1097\/MD.0000000000011933","article-title":"Two Case Reports of Pyoderma Gangrenosum and Systemic Lupus Erythematosus","volume":"97","author":"Lebrun","year":"2018","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"He, R., Zhao, S., Cui, M., Chen, Y., Ma, J., Li, J., and Wang, X. (2023). Cutaneous Manifestations of Inflammatory Bowel Disease: Basic Characteristics, Therapy, and Potential Pathophysiological Associations. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1234535"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s10620-019-05999-4","article-title":"Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"65","author":"States","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.0906-6705.2003.00088.x","article-title":"Increased E-selectin, IL-8 and IL-10 Gene Expression in Human Skin after Minimal Trauma","volume":"12","author":"Takeuchi","year":"2003","journal-title":"Exp. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Marzano, A.V., Ortega-Loayza, A.G., Heath, M., Morse, D., Genovese, G., and Cugno, M. (2019). Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01059"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 Pathogenic Axis in Psoriasis Is Amplified by Keratinocyte Responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjd.13670","article-title":"The Treg\/Th17 Cell Ratio Is Reduced in the Skin Lesions of Patients with Pyoderma Gangrenosum","volume":"173","author":"Caproni","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/CCID.S61202","article-title":"Pyoderma Gangrenosum: Challenges and Solutions","volume":"8","author":"Gameiro","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jeucken, K.C.M., Koning, J.J., Mebius, R.E., and Tas, S.W. (2019). The Role of Endothelial Cells and TNF-Receptor Superfamily Members in Lymphoid Organogenesis and Function During Health and Inflammation. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02700"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1189\/jlb.0607421","article-title":"Role of TNF Priming and Adhesion Molecules in Neutrophil Recruitment to Intravascular Immune Complexes","volume":"83","author":"Lauterbach","year":"2008","journal-title":"J. Leucoc. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"\u0141yko, M., Rygu\u0142a, A., Kowalski, M., Karska, J., and Jankowska-Konsur, A. (2024). The Pathophysiology and Treatment of Pyoderma Gangrenosum\u2014Current Options and New Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042440"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12325-018-0678-0","article-title":"Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn\u2019s Disease: A Pooled Analysis of 11 Clinical Studies","volume":"35","author":"Louis","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ecco-jcc\/jjx093","article-title":"Effect of Adalimumab on Clinical Outcomes and Health-Related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results from InspirADA","volume":"11","author":"Travis","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the Induction and Maintenance of Clinical Remission in Japanese Patients with Crohn\u2019s Disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1203475420917387","article-title":"Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study","volume":"24","author":"Cossio","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","article-title":"Efficacy of Adalimumab for the Treatment of Extraintestinal Manifestations of Crohn\u2019s Disease","volume":"104","author":"Lorenzo","year":"2012","journal-title":"Rev. Esp. Enfermedades Dig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e04690","DOI":"10.1002\/ccr3.4690","article-title":"Whether to Maintain or Strengthen the Treatment for Pyoderma Gangrenosum Ulcerative Type May Depend on the Response after Two to Four-week Treatment Intervention: The Outcome of Three Cases with Details Clinical Course","volume":"9","author":"Nakayama","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/ijd.13591","article-title":"Pyoderma Gangrenosum: Clinical Characteristics, Associated Diseases, and Responses to Treatment in a Retrospective Cohort Study of 31 Patients","volume":"56","author":"Vacas","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1358\/dot.2021.57.9.3293619","article-title":"An Update on Adalimumab for Pyoderma Gangrenosum","volume":"57","author":"Yamamoto","year":"2021","journal-title":"Drugs Today"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/1346-8138.15533","article-title":"Adalimumab in Japanese Patients with Active Ulcers of Pyoderma Gangrenosum: Twenty-six-week Phase 3 Open-label Study","volume":"47","author":"Yamasaki","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1346-8138.16337","article-title":"Adalimumab in Japanese Patients with Active Ulcers of Pyoderma Gangrenosum: Final Analysis of a 52-week Phase 3 Open-label Study","volume":"49","author":"Yamasaki","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1002\/ibd.21723","article-title":"Adalimumab for Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease","volume":"17","author":"Acosta","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/1346-8138.17547","article-title":"Real-world Safety and Effectiveness of Adalimumab in Patients with Pyoderma Gangrenosum: Interim Analysis of a Post-marketing Observational Study in Japan","volume":"52","author":"Yamamoto","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_41","first-page":"32","article-title":"Biologics and Immunoglobulins in the Treatment of Pyoderma Gangrenosum\u2014Analysis of 52 Patients","volume":"17","author":"Herberger","year":"2019","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","article-title":"Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease","volume":"58","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"770","DOI":"10.4103\/idoj.idoj_843_23","article-title":"Clinicopathological Profile of Pyoderma Gangrenosum: A 10-Year Retrospective Study from a Tertiary Care Center in South India","volume":"15","author":"George","year":"2024","journal-title":"Indian Dermatol. Online J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WON.0000000000000763","article-title":"Topical Management of Peristomal Pyoderma Gangrenosum","volume":"48","author":"Toyoda","year":"2021","journal-title":"J. Wound Ostomy Cont. Nurs."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.25259\/IJDVL_700_2023","article-title":"Topical Treatment of Pyoderma Gangrenosum: A Systematic Review","volume":"91","author":"Donnelly","year":"2024","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse Effects of Topical Glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1365-2133.2004.05914.x","article-title":"Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum","volume":"150","author":"Ghislain","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/120347541201600503","article-title":"Successful Treatment of Localized Pyoderma Gangrenosum with Topical Pimecrolimus","volume":"16","author":"Cecchi","year":"2012","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00004836-198512000-00011","article-title":"Intralesional Steroid Therapy of Pyoderma Gangrenosum","volume":"7","author":"Goldstein","year":"1985","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_50","first-page":"151","article-title":"A Comprehensive Review of Local Pharmacologic Therapy for Pyoderma Gangrenosum","volume":"31","author":"Baltazar","year":"2019","journal-title":"Wounds"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000246377","article-title":"Topical Treatment with 1% Sodium Cromoglycate in Pyoderma Gangrenosum","volume":"192","author":"Tamir","year":"1996","journal-title":"Dermatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0190-9622(96)90285-6","article-title":"Treatment of Pyoderma Gangrenosum","volume":"34","author":"Chow","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.metabol.2014.06.005","article-title":"Efficacy of Topical Recombinant Human Platelet-Derived Growth Factor for Treatment of Diabetic Lower-Extremity Ulcers: Systematic Review and Meta-Analysis","volume":"63","author":"Zhao","year":"2014","journal-title":"Metabolism"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.jaad.2014.07.060","article-title":"Collagenase Ointment and Topical Timolol Gel for Treating Idiopathic Pyoderma Gangrenosum","volume":"71","author":"Liu","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1089\/wound.2020.1168","article-title":"A Wound Care Specialist\u2019s Approach to Pyoderma Gangrenosum","volume":"9","author":"Croitoru","year":"2020","journal-title":"Adv. Wound Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000362724","article-title":"One Hormone, Two Actions: Anti- and Pro-Inflammatory Effects of Glucocorticoids","volume":"22","author":"Cidlowski","year":"2015","journal-title":"Neuroimmunomodulation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000481432","article-title":"Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients","volume":"233","author":"Kolios","year":"2017","journal-title":"Dermatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1111\/1346-8138.16845","article-title":"Clinical Guidance of Pyoderma Gangrenosum 2022","volume":"50","author":"Yamamoto","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.det.2023.12.002","article-title":"Treatment of Pyoderma Gangrenosum","volume":"42","author":"Tan","year":"2024","journal-title":"Dermatol. Clin."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"h2958","DOI":"10.1136\/bmj.h2958","article-title":"Comparison of the Two Most Commonly Used Treatments for Pyoderma Gangrenosum: Results of the STOP GAP Randomised Controlled Trial","volume":"350","author":"Ormerod","year":"2015","journal-title":"BMJ"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/bjd.15561","article-title":"Ciclosporin Compared with Prednisolone Therapy for Patients with Pyoderma Gangrenosum: Cost-Effectiveness Analysis of the STOP GAP Trial","volume":"177","author":"Mason","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/09546631003686069","article-title":"Pyoderma Gangrenosum: Study of 21 Patients and Proposal of a \u2018Clinicotherapeutic\u2019 Classification","volume":"22","author":"Marzano","year":"2011","journal-title":"J. Dermatol. Treat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/apt.17938","article-title":"Effectiveness and Safety of a Third-line Rescue Treatment for Acute Severe Ulcerative Colitis Refractory to Infliximab or Ciclosporin (REASUC Study)","volume":"59","author":"Riestra","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00403-024-03332-2","article-title":"Use of biologic therapies in the management of pyoderma gangrenosum: A systematic review","volume":"316","author":"Zaman","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_66","first-page":"9630","article-title":"Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn\u2019s disease","volume":"15","author":"Miklusiak","year":"2023","journal-title":"Dermatol. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2050313X20940430","DOI":"10.1177\/2050313X20940430","article-title":"Pyoderma gangrenosum treated with secukinumab: A case report","volume":"8","author":"McPhie","year":"2020","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ced.14809","article-title":"Anakinra for recalcitrant pyoderma gangrenosum","volume":"46","author":"Gallagher","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jdcr.2019.04.019","article-title":"Pyoderma gangrenosum controlled with rituximab","volume":"5","author":"DaCunha","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/bjd.20474","article-title":"Comorbidities, Mortality and Survival in Patients with Pyoderma Gangrenosum: A Danish Nationwide Registry-nested Case\u2013Control Study","volume":"185","author":"Bech","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaad.2018.02.007","article-title":"The Impact of Underlying Disease State on Outcomes in Patients with Pyoderma Gangrenosum: A National Survey","volume":"79","author":"Kaffenberger","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_72","first-page":"e51490","article-title":"Pyoderma Gangrenosum: The Impact of Treatment Non-adherence on Disease Progression","volume":"16","author":"Iliescu","year":"2024","journal-title":"Cureus"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/3\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:23Z","timestamp":1760028623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/3\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["clinpract15030057"],"URL":"https:\/\/doi.org\/10.3390\/clinpract15030057","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}